Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
Journal of Antimicrobial Chemotherapy2010Vol. 65(5), pp. 1005–1007
Citations Over TimeTop 21% of 2010 papers
Véronique Avettand-Fènoël, Philippe Flandre, Marie‐Laure Chaix, Jade Ghosn, Constance Delaugerre, François Raffi, P. NgoVan, Isabelle Cohen-Codar, J. F. Delfraissy, C. Rouzioux, on behalf of the MONARK study group
Abstract
The MONARK data indicate that a lopinavir/ritonavir monotherapy regimen is potent against HIV blood reservoirs in antiretroviral-naive patients after 1 year of treatment, in comparison with a standard-of-care highly active antiretroviral therapy. This impact should be evaluated with other boosted protease inhibitor monotherapies.
Related Papers
- → Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019(2020)39 cited
- → Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir(2009)27 cited
- → Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice‐Daily to Once‐Daily Therapy(2007)17 cited
- PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.(2015)
- → Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir(2012)3 cited